Hongchang International Co., Ltd
Hongchang International Co., Ltd (HCIL): 1 pipeline candidate · ~29 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
28.5 months
D/E 0.52 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for Hongchang International Co., Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$60.7M
Cash
$778K
Quarterly Burn
$316K
Runway
28.5 mo
Revenue
$4.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| submillimeter wave quantized space therapy chamber | Preclinical |
Frequently asked questions
How many drug candidates are in Hongchang International Co., Ltd's pipeline?
Hongchang International Co., Ltd (HCIL) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Hongchang International Co., Ltd's lead drug candidate?
Hongchang International Co., Ltd's most advanced tracked candidate is submillimeter wave quantized space therapy chamber (Preclinical) for cancer.
What is Hongchang International Co., Ltd's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Hongchang International Co., Ltd has approximately 28.5 months of cash runway.
What is Hongchang International Co., Ltd's market capitalization?
Hongchang International Co., Ltd's market capitalization is approximately $60.7M.
Who is the CEO of Hongchang International Co., Ltd?
Mr. Zengqiang Lin is the chief executive officer of Hongchang International Co., Ltd (HCIL).
Get the full picture on Hongchang International Co., Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.